For eligible patients,
PHESGO COMBINES PERJETA® (pertuzumab) AND HERCEPTIN® (trastuzumab) INTO A SINGLE INJECTION FOR HER2+ BREAST CANCER1
See how you may save time for your patients and practice with PHESGO1
For eligible patients,
PHESGO COMBINES PERJETA® (pertuzumab) AND HERCEPTIN® (trastuzumab) INTO A SINGLE INJECTION FOR HER2+ BREAST CANCER1
See how you may save time for your patients and practice with PHESGO1
PHESGO is a fixed-dose subcutaneous treatment that’s administered in ~5 minutes.*1
*Refers to actual PHESGO injection time of ~5 minutes for the maintenance dose. The loading dose is ~8 minutes. This does not account for observation time and other aspects of treatment. Actual clinic time may vary.1
NCCN=National Comprehensive Cancer Network® (NCCN®).
PHESGO is FDA approved for all of the same HER2+ breast cancer indications as PERJETA.1,2
Watch a video tutorial with instructions for preparing and administering PHESGO.
Learn how PHESGO compares to IV PERJETA + trastuzumab, and see the patient preference data.
Most major insurance plans provide coverage for PHESGO.*3
*Data current as of 05/2024. Insurer policies may vary and are subject to change.3
PHESGO Prescribing Information. Genentech, Inc. 2020.
PHESGO Prescribing Information. Genentech, Inc. 2020.
PERJETA Prescribing Information. Genentech, Inc. 2021.
PERJETA Prescribing Information. Genentech, Inc. 2021.
Data on file. Genentech, Inc. MMIT Analysis. HLI Lives Database.
Data on file. Genentech, Inc. MMIT Analysis. HLI Lives Database.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.